Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- QBiotics Group Limited
- Target Recruit Count
- 40
- Registration Number
- NCT05755113
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Centre, New York, New York, United States
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- QBiotics Group Limited
- Target Recruit Count
- 20
- Registration Number
- NCT05608876
- Locations
- 🇦🇺
The Kinghorn Cancer Centre, Sydney, New South Wales, Australia
🇦🇺Metro South Hospital and Health Service, via the Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇬🇧East and North Hertfordshire NHS Trust (Incorporating Mount Vernon Cancer Centre) of Lister Hospital, Stevenage, Hertfordshire, United Kingdom
A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- QBiotics Group Limited
- Target Recruit Count
- 1
- Registration Number
- NCT05234437
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
🇦🇺Cairns and Hinterland Hospital and Health Service, Cairns, Queensland, Australia
🇦🇺Metro South Hospital and Health Service via Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- QBiotics Group Limited
- Target Recruit Count
- 3
- Registration Number
- NCT04834973
- Locations
- 🇦🇺
Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
🇦🇺Cairns and Hinterland Hospital and Health Service, Cairns, Queensland, Australia
News
Promising Pipeline for Soft Tissue Sarcoma Treatment Expands with 130+ Therapies in Development
Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.
Pipeline Advances in Head and Neck Cancer Treatment: Over 100 Drugs in Development for 2025
DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area.
FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma Treatment
The FDA has awarded orphan drug designation to tigilanol tiglate (Stelfonta), an intratumoral injection, for treating soft tissue sarcoma, a rare cancer affecting both adults and children.